01 · The promise
For labs running EuroFlow panels
The immunophenotyping capability of a six-figure clinical flow cytometer,
on the ~€6.0k VeraFab reader.
A single-use silicon-photonics chip runs your EuroFlow panels on a benchtop reader — lighter reagent load, no service contract. We're proving it against labs' own panels right now. See what it could recover on yours, then help us put the concordance data behind it.
Analysis your clinicians can openNo monthly compensation matrixStandardised site to siteReproducible run to runAutomated daily QC reportLoad and run in minutes
By construction — concordance in validation on your own samples.
Your numbers, right nowplanning estimate
€172k
Recoverable per site, per year
under a month
Reader payback
€517k
Across 3 sites
Research use today. CE-IVD and UKCA are a validation and QMS pathway ahead, sequenced with the founding cohort — not a released status. Every figure here is indicative until validated on your own samples during the pilot — not a clinical or regulatory claim.
We won't show you a concordance plot we haven't earned. Here's where the evidence stands.
See it as the budget case, or the bench case.
02 · Your numbers
Your workload
Start from a lab like yours, then fine-tune.
SITES
3 sites
4 panels · 3 sites · Typical haematology lab
The capability case · before the money
Answers the interpretation gap
One shareable, out-of-the-box analysis layer across every site — the referring clinician opens the same gates the bench did. It answers the "software to interpret results" gap directly (concordance in validation).
Standardised across sites
One chip, one reader model, factory-calibrated readout, so a result in one site reproduces in another — cross-site reference-range consistency by construction (in validation).
The panels your cytometer runs, on a ~€6.0k reader
EuroFlow immunophenotyping — the panels your six-figure clinical cytometer runs today — on a single-use chip and a benchtop reader. Cost is the tie-breaker below, not the reason.
The budget case · 3 sites
The P&L backup to the capability case above — cost is the tie-breaker, not the driver.
€172k
Recoverable per site, per year
under a month
Reader payback
€517k
Across 3 sites
Reader lets you retire or avoid replacing an instrument?
Off by default — we count reagent and consumables only. Turn it on only if the reader's routine-screening volume lets you retire an ageing analyser or skip its next replacement. Your confirmatory Cytek/BD stays for deep panels and MRD; this just adds that retired instrument's service-contract saving.
The mechanism · per case: your tubes vs one chip
The auditable line — what a single case costs today against the VeraFab reader.
AML / MDS
7 tubes · 1/day/site
Current€321
VeraFab€45
€276
saved / case
B-CLPD
5 tubes · 1/day/site
Current€231
VeraFab€45
€186
saved / case
LST
1 tube · 4/day/site
Current€51
VeraFab€10
€41
saved / case
+ 1 more panel in the full breakdown below.
How firm is each euro? · per site / year
Defensible today
€0 until you confirm above you'll retire or skip replacing an instrument. Even so: ~€6.0k per reader vs a six-figure clinical cytometer, same method.
In validation (reagent-real)
Deep panels — your multi-tube AML/MDS and classification reagent load vs one chip. Doesn't touch your screening method. In validation on labs' own samples now.
Aspirational (flagged upside)
Reagent-free screening via AI virtual staining — in validation. Zero this line out and the case above still stands on its own.
On-chip spectral multiplexing runs a multi-tube panel as fewer chips — that's why one chip can stand in for several tubes (in validation).
Why this is conservative
Chips are priced at the complex-panel end, deep panels keep a residual reagent load, labour is off, and the service saving stays off until you confirm the reader retires your incumbent. The reagent lines on the deep panels carry the case without touching your screening method — tighten anything in Assumptions.What stays the same
We replace the flow-cytometry screening and classification step, not the workflow. No serology, molecular (PCR/NGS/ctDNA), cytogenetics (karyotype/FISH), mass spec, or histology — and deep-sensitivity EuroFlow MRD stays on your reference analyser. Those aren't in these numbers.03 · Partner
Wherever you run EuroFlow today
EuroFlow panels run on conventional 8-colour cytometers — that's the comparison across this page. Two starting points, one chip.
You run conventional flow cytometry
BD FACSCanto / FACSLyric, Beckman. The reader takes out most of the antibody-reagent, service-contract and bench-time cost of running these panels. The honest trade-off: we're research-use today, not IVD — so we start alongside your validated analyser, not in place of it.
You're moving to spectral
Cytek Aurora, Sony ID7000 · €350k–€500k. Our chip runs the same panels for a ~€6.0k reader. And because the spectral platforms are research-use for these panels too, going spectral wouldn't gain you IVD status either — so you give up nothing on regulatory standing, at a fraction of the capital.
How a pilot runs
A blinded side-by-side on your own residual samples — research / parallel use, outside your ISO 15189 scope, so it creates no nonconformity. Who does what:
| Step | Your lab | Us |
|---|---|---|
| Scope | Pick 1–2 panels and set aside residual samples after your routine run. | Supply the validation protocol and place the reader on site — no capital outlay. |
| Run | Run your samples on your own instrument, as you do today. | Run the same samples on the chip, blinded to your result. |
| Analyse | Open the shareable analysis and gate as you normally would. | Report population-level concordance vs your instrument — a blast gate, CD34/CD117, a lineage call. |
| Compatibility | Keep your existing tools — FCS exports drop into FlowJo / Infinicyt / Kaluza. | No new software seat; we fit your workflow, not the other way round. |
| Keep the data | Keep every file, and walk away anytime. | Co-authorship on the EuroFlow comparison dataset. |
Easier biological validation, not just a cheaper box
Prep is sealed on-cartridge and the readout is batch-calibrated, so run-to-run and site-to-site variation shrinks by construction — the biological validation you'd run for any new method has fewer moving parts. We supply the protocol; you validate against your own ground truth, and the regulatory footing stays yours: parallel research use, no nonconformity.Become a design partner
Prove it on your own residual samples
We're taking a small first cohort of European haematology labs — partner pricing locked, priority on validating your panels, and co-authorship on the EuroFlow comparison. The first step is a blinded side-by-side on your own leftover samples, not a purchase.
What a pilot costs you
No capital outlay — we place the reader. You run your own residual samples in parallel on your own instrument. Research / parallel use only: no clinical reporting, outside your ISO 15189 scope, so it creates no nonconformity — and we supply the validation protocol. You keep the data, and walk away anytime.Where the evidence stands. What we've shown so far: label-free leukocyte differentiation (Yoon et al., 2017) and CTC morphology (APL Bioengineering, 2023). What this cohort builds: the EuroFlow concordance dataset that doesn't exist yet. Scientific advisory being announced with the founding cohort.
We use your details only to follow up on this pilot. We don't share them or add you to a mailing list. Your savings inputs travel with the request so the first conversation is about your numbers.